GlobalRPh Renal Dosing Masterv7.4
Renal Dosing Master: fast drug lookup
Source review / handoff

Lemborexant (Dayvigo), oral tablet

One or two intact local summaries. No averaged regimen, patient-specific dose or automatic source preference.

Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.

Share or print this source review

1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.

Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.

Clinical context remains essential

Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.

Check source scope before reading a dose

Dayvigo - labeled renal guidance

Product / population
Lemborexant (Dayvigo), oral tablet
Renal method
Renal impairment categories as defined by the cited product label
Source revision
DailyMed SPL version 39, posted Mar 03, 2025
Retrieved
2026-11-07
Local review status
Selected renal passages reviewed; independent clinician adjudication pending.

Documented differences and cautions on this drug

All record notes are retained here, including notes about sources not selected in this review.

Dayvigo - product and source limitations

Assess next-day impairment and other sedating medicines.

What to reconcile: Apply only to the stated formulation, indication and renal population.

Selected renal passages reviewed; independent clinician adjudication pending.

Open this note and its source references
Official

Dayvigo - labeled renal guidance

Open original reference

DailyMed / product prescribing information · Lemborexant (Dayvigo), oral tablet

Renal method: Renal impairment categories as defined by the cited product label
Source date: DailyMed SPL version 39, posted Mar 03, 2025
Retrieved: 2026-11-07

Qualified no-adjustment statement. Apply only to the population, product and renal range described in this source.

Selected renal passages reviewed; independent clinician adjudication pending.

Renal guidance: 8.6 Renal Impairment

No renal adjustment is specified from mild through severe impairment. Increased exposure in severe impairment may increase somnolence. Assess next-day impairment and other sedating medicines.

RDM74-dayvigo-official-1 · Source locator: Renal guidance: 8.6 Renal Impairment

Source identity and provenance
Source family
product_label
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7074cb65-77b3-45d2-8e8d-da8dc0f70bfd
Retrieved
2026-11-07
Renal-function method
Renal impairment categories as defined by the cited product label
Source date/version
DailyMed SPL version 39, posted Mar 03, 2025
Hash meaning
SHA-256 of the local selected-source summary
Local summary SHA-256
ac46e301cf8dd8f5d1266f737a79dfc2ce05b32a9a448f0cb9c158c4e7368ccd

Document the clinical decision separately

This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.

GlobalRPh Renal Dosing Master v7.4. Review the retrieval and revision dates attached to each source. Selecting a reference does not imply clinical verification.

Pinned reference: https://globalrph.com/blogCalcs/renal-dosing-master/compare.php?id=rx-dayvigo&s1=RDM74-dayvigo-official&h1=cadedfd49df6f8a78a9223fc19e6596b0fd0cfd9ab304ef000e7f55e064072ce

Top